Track OliX Pharmaceuticals,Inc — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

OliX Pharmaceuticals,Inc 226950.KQ · Stock Open OliX Pharmaceuticals,Inc in new tab

172800.00 KRW
Add to portfolio
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Debt/Equity14.99
% Insiders17.099%
Growth
Revenue Growth2.66%
Estimates
Forward P/E-137.58

DCF Valuation

Tweak assumptions to recompute fair value for OliX Pharmaceuticals,Inc (226950.KQ)
Currency: KRW
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

OliX Pharmaceuticals,Inc Logo OliX Pharmaceuticals,Inc Analysis (226950.KQ)

South Korea Healthcare Official Website Stock

Is OliX Pharmaceuticals,Inc a good investment? OliX Pharmaceuticals,Inc (226950.KQ) is currently trading at 172800.00 KRW.

Investor FAQ

Does OliX Pharmaceuticals,Inc pay a dividend?

No, it does not currently pay a dividend.

What asset class is OliX Pharmaceuticals,Inc?

OliX Pharmaceuticals,Inc is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

Company Profile

OliX Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company's products pipeline includes OLX101A for skin scar; OLX104C for androgenic alopecia; OLX301A for age-related macular degeneration; OLX702A for metabolic dysfunction-associated steatohepatitis; OLX703A for hepatitis; and OLX301D for subretinal fibrosis. The company has a license and collaboration agreement with Hansoh Pharmaceuticals; development collaboration with Korea Institute of Technology; and research collaboration with the University of Virginia. The company was formerly known as Biomolecular Therapeutics Inc. OliX Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Suwon-si, South Korea.

Exchange Ticker
KOE 226950.KQ
Trades
Dividend History paid per year (KRW)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Dec. 3, 2020 2.000000
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion